Press release
TIGIT Inhibitor Clinical Pipeline Strengthens as 14+ Companies Advance 18+ Novel Immunotherapy Candidates | DelveInsight
TIGIT Inhibitor Clinical Trial
DelveInsight's latest report, "TIGIT Inhibitor Pipeline Insight 2026 [https://www.delveinsight.com/report-store/tigit-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]," provides a comprehensive analysis of the rapidly evolving TIGIT inhibitor landscape. The study highlights the contributions of over 14 leading pharmaceutical and biotechnology companies developing more than 18 pipeline therapies targeting TIGIT, an emerging immune checkpoint in oncology.
The report offers detailed insights into both clinical and preclinical drug candidates, along with a thorough evaluation based on product type, development stage, route of administration, and molecular class. Additionally, it sheds light on discontinued and inactive programs, providing a complete view of the pipeline ecosystem.
Explore the latest updates in the TIGIT inhibitor pipeline and ongoing clinical trials: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight [https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the TIGIT Inhibitor Pipeline Report
* As of January 2026, AstraZeneca initiated a Phase III clinical study evaluating trastuzumab deruxtecan (T-DXd) in combination with rilvegostomig or pembrolizumab compared to chemotherapy plus pembrolizumab as a first-line treatment for HER2-expressing advanced or recurrent endometrial cancer.
* The TIGIT inhibitor pipeline demonstrates strong momentum, with over 14 companies actively engaged in advancing more than 18 innovative therapies.
* Prominent companies operating in this space include Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, and others.
* Key investigational and combination therapies include zimberelimab, domvanalimab, pembrolizumab, quavonlimab, vibostolimab, trastuzumab deruxtecan, rilvegostomig, and more.
Discover which companies are leading innovation in TIGIT-targeted therapies: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight [https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Overview of TIGIT as a Therapeutic Target
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as a promising immune checkpoint target in cancer immunotherapy. TIGIT is a transmembrane receptor expressed on activated T cells, natural killer (NK) cells, and regulatory T cells.
It interacts with ligands such as CD155 and CD112 on antigen-presenting cells, leading to immune suppression and reduced anti-tumor activity. Targeting TIGIT can help restore immune function, enhance T-cell activation, and improve NK cell-mediated tumor responses, making it an attractive approach in oncology drug development.
Emerging Drug Profiles in the TIGIT Inhibitor Space
Tiragolumab - Genentech
Tiragolumab is a monoclonal antibody designed to inhibit TIGIT by preventing its interaction with CD155. This blockade helps restore immune activity, particularly when combined with PD-L1 inhibitors, resulting in enhanced T-cell activation and improved anti-tumor responses.
Ociperlimab - BeiGene
Ociperlimab (BGB-A1217) is an investigational monoclonal antibody with high specificity for TIGIT. It blocks interactions with CD155 and CD112, thereby promoting T-cell-mediated immune responses against tumors. With an optimized Fc region, ociperlimab is among the most advanced anti-TIGIT therapies under development.
Stay updated on the latest TIGIT inhibitor clinical trials and drug developments: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight [https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Comprehensive Pipeline and Therapeutic Assessment
The report delivers an in-depth analysis of the TIGIT inhibitor pipeline, including:
* Detailed profiling of companies developing targeted therapies
* Segmentation of pipeline candidates across early, mid, and late-stage development
* Evaluation of both active and discontinued programs
* Classification of drugs based on mechanism of action, route of administration, and molecular type
* Comparative insights into monotherapies and combination therapies
It also provides extensive information on strategic collaborations, licensing deals, mergers, acquisitions, and funding activities shaping the future of TIGIT-targeted therapeutics.
Key Companies in the TIGIT Inhibitor Landscape
Leading players contributing to the development of TIGIT inhibitors include Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, and Bio-Thera Solutions, among others.
Phases
DelveInsight's report covers around 18+ products under different phases of clinical development like
* Late-stage products (Phase III and
* Mid-stage products (Phase II and
* Early-stage products (Phase I/II and Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Route of Administration
TIGIT Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical
Molecule Type
Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the TIGIT Inhibitor Pipeline Report
* Coverage- Global
* TIGIT Inhibitor Companies- Genentech, BeiGene, Arcus Biosciences, iTeos Therapeutics, Merck KGaA, Curocell, Agenus, Compugen, Tasrif Pharmaceutical, Y-Biologics, Aurigene, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, and others.
* TIGIT Inhibitor Therapies- Zimberelimab, Domvanalimab, Pembrolizumab, Quavonlimab, Vibostolimab, Trastuzumab deruxtecan, Rilvegostomig, and others.
* TIGIT Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* TIGIT Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Gain a complete view of the TIGIT inhibitor pipeline and future opportunities: https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight [https://www.delveinsight.com/sample-request/tigit-inhibitors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Strategic Insights and Future Outlook
The TIGIT inhibitor space represents one of the most promising areas in immuno-oncology, with increasing interest from both established pharmaceutical companies and emerging biotech firms. The growing focus on combination therapies, particularly with PD-1/PD-L1 inhibitors, is expected to unlock new therapeutic potential and improve patient outcomes.
As clinical trials progress and more data becomes available, TIGIT inhibitors are anticipated to play a significant role in the next generation of cancer immunotherapies.
Table of Contents
1. Introduction
2. Executive Summary
3. TIGIT Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. TIGIT Inhibitors - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tiragolumab: Genentech
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. MK-7684A: Merck
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. M 6223: Merck
15. Drug profiles in the detailed report.....
16. Pre-clinical and Discovery Stage Products
17. TSRF 786C: Tasrif Pharmaceutical
18. Drug profiles in the detailed report.....
19. Inactive Products
20. TIGIT Inhibitors Key Companies
21. TIGIT Inhibitors Key Products
22. TIGIT Inhibitors- Unmet Needs
23. TIGIT Inhibitors- Market Drivers and Barriers
24. TIGIT Inhibitors- Future Perspectives and Conclusion
25. TIGIT Inhibitors Analyst Views
26. TIGIT Inhibitors Key Companies
27. Appendix
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm dedicated to the life sciences industry. The company provides high-quality market intelligence, competitive analysis, and strategic insights to help organizations make informed business decisions.
With deep expertise in healthcare and a global perspective, DelveInsight delivers customized solutions to support innovation and growth across pharmaceutical and biotech sectors.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tigit-inhibitor-clinical-pipeline-strengthens-as-14-companies-advance-18-novel-immunotherapy-candidates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release TIGIT Inhibitor Clinical Pipeline Strengthens as 14+ Companies Advance 18+ Novel Immunotherapy Candidates | DelveInsight here
News-ID: 4444087 • Views: …
More Releases from ABNewswire
AgeRejuvenation Utilizes Advanced Gut Health Analysis in South Tampa to Resolve …
SOUTH TAMPA, FL - March 27, 2026 - AgeRejuvenation utilizes advanced gut health analysis in South Tampa as a primary diagnostic tool to identify the specific microbial imbalances linked to chronic inflammation and metabolic fatigue. The clinical team focuses on comprehensive microbiome testing to uncover the underlying factors that contribute to digestive dysfunction and nutrient malabsorption. This service spotlight emphasizes the clinic's commitment to data-driven wellness for men and women…
Thyroid Cancer Clinical Trial Pipeline Shows Potential with Active Contributions …
DelveInsight's, "Thyroid Cancer Pipeline Insight 2026" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive Thyroid Cancer Pipeline Report…
TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leadi …
DelveInsight's, "Transforming Growth Factor Beta Inhibitors Pipeline Insight 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Transforming Growth Factor Beta Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the…
PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therap …
DelveInsight's "PD-1 and PD-L1 Inhibitors Competitive landscape 2026" report provides comprehensive insights about 180+ companies and 200+ drugs in the PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving PD-1 and PD-L1 Inhibitors Pipeline @ PD-1 and PD-L1 Inhibitors Competitive Landscape Report…
More Releases for TIGIT
Development and Optimization of Next-Generation TIGIT Antibodies
The development and optimization of next-generation TIGIT antibodies represent a significant advancement in cancer immunotherapy. These antibodies are designed to target the TIGIT immune checkpoint more effectively, offering improved therapeutic potential for enhancing anti-tumor immune responses.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
The initial development of TIGIT antibodies focused on blocking the interaction between TIGIT and its ligands, CD155 and CD112. By preventing this binding, the inhibitory signals transmitted by TIGIT are lifted, allowing immune cells…
The Future of TIGIT Antibodies in Personalized Cancer Treatment
The future of TIGIT antibodies in personalized cancer treatment looks promising, with the potential to revolutionize the way we approach cancer therapy. Personalized medicine aims to tailor treatments based on individual patient characteristics, including genetic, molecular, and immune profiles. TIGIT antibodies, by targeting a specific immune checkpoint, offer a new avenue for customizing cancer treatment and improving patient outcomes.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
TIGIT, an inhibitory receptor expressed on T cells, NK cells, and…
Comparative Effectiveness of TIGIT Antibodies and Other Checkpoint Inhibitors
The comparative effectiveness of TIGIT antibodies and other checkpoint inhibitors is a topic of significant interest in the field of cancer immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to attack tumors. While PD-1 and CTLA-4 inhibitors have shown remarkable success, TIGIT antibodies offer a new approach with potentially complementary mechanisms.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1 receptor on T…
Biomarkers for Predicting Response to TIGIT Antibody Therapy
Identifying biomarkers for predicting response to TIGIT antibody therapy is crucial for optimizing treatment outcomes and personalizing cancer therapy. Biomarkers can help select patients who are most likely to benefit from TIGIT blockade, thereby improving the efficacy and reducing unnecessary exposure to the therapy.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
One of the most promising biomarkers for TIGIT antibody therapy is the expression level of CD155, the primary ligand for TIGIT. High levels of CD155 expression…
Innovations in Immunotherapy The Rise of Anti TIGIT Antibodies
Innovations in immunotherapy have transformed the landscape of cancer treatment, offering new hope to patients who previously had limited options. Among these innovations, the rise of anti-TIGIT antibodies represents a significant advancement in the field, providing a novel approach to enhancing the immune system's ability to combat cancer. Anti-TIGIT antibodies are a new class of immune checkpoint inhibitors that target TIGIT, an inhibitory receptor expressed on T-cells, natural killer (NK)…
Anti TIGIT Antibodies Revolutionizing Immunotherapy
Anti-TIGIT antibodies are at the forefront of a revolution in immunotherapy, representing a new class of immune checkpoint inhibitors that have the potential to transform the treatment landscape for cancer. Immunotherapy, which harnesses the body's immune system to fight cancer, has already made significant strides with the introduction of PD-1, PD-L1, and CTLA-4 inhibitors. However, the discovery and development of anti-TIGIT antibodies add a new dimension to this field, offering…
